Article thumbnail

Massive APOBEC3 Editing of Hepatitis B Viral DNA in Cirrhosis

By Jean-Pierre Vartanian, Michel Henry, Agnès Marchio, Rodolphe Suspène, Marie-Ming Aynaud, Denise Guétard, Minerva Cervantes-Gonzalez, Carlo Battiston, Vincenzo Mazzaferro, Pascal Pineau, Anne Dejean and Simon Wain-Hobson


DNA viruses, retroviruses and hepadnaviruses, such as hepatitis B virus (HBV), are vulnerable to genetic editing of single stranded DNA by host cell APOBEC3 (A3) cytidine deaminases. At least three A3 genes are up regulated by interferon-α in human hepatocytes while ectopic expression of activation induced deaminase (AICDA), an A3 paralog, has been noted in a variety of chronic inflammatory syndromes including hepatitis C virus infection. Yet virtually all studies of HBV editing have confined themselves to analyses of virions from culture supernatants or serum where the frequency of edited genomes is generally low (≤10−2). We decided to look at the nature and frequency of HBV editing in cirrhotic samples taken during removal of a primary hepatocellular carcinoma. Forty-one cirrhotic tissue samples (10 alcoholic, 10 HBV+, 11 HBV+HCV+ and 10 HCV+) as well as 4 normal livers were studied. Compared to normal liver, 5/7 APOBEC3 genes were significantly up regulated in the order: HCV±HBV>HBV>alcoholic cirrhosis. A3C and A3D were up regulated for all groups while the interferon inducible A3G was over expressed in virus associated cirrhosis, as was AICDA in ∼50% of these HBV/HCV samples. While AICDA can indeed edit HBV DNA ex vivo, A3G is the dominant deaminase in vivo with up to 35% of HBV genomes being edited. Despite these highly deleterious mutant spectra, a small fraction of genomes survive and contribute to loss of HBeAg antigenemia and possibly HBsAg immune escape. In conclusion, the cytokine storm associated with chronic inflammatory responses to HBV and HCV clearly up regulates a number of A3 genes with A3G clearly being a major restriction factor for HBV. Although the mutant spectrum resulting from A3 editing is highly deleterious, a very small part, notably the lightly edited genomes, might help the virus evolve and even escape immune responses

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2009). A novel mouse model of hepatocarcinogenesis triggered by AID causing deleterious p53 mutations.
  2. (1999). A read-ahead function in archaeal DNA polymerases detects promutagenic template-strand uracil.
  3. (2004). A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor.
  4. (2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.
  5. (2007). Activationinduced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells.
  6. (2008). Activationinduced cytidine deaminase links between inflammation and the development of colitis-associated colorectal cancers.
  7. (1997). Altered antigenicity of ‘a’ determinant variants of hepatitis B virus.
  8. (2002). An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22.
  9. (2006). Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes.
  10. (1997). Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants.
  11. (2010). APOBEC3 proteins mediate the clearance of foreign DNA from human cells.
  12. (2005). APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses.
  13. (2004). APOBEC3G genetic variants and their influence on the progression to AIDS.
  14. (2004). APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase.
  15. (2008). APOBEC3G upregulation by alpha interferon restricts human immunodeficiency virus type 1 infection in human peripheral plasmacytoid dendritic cells.
  16. (1995). Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals.
  17. (2003). Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
  18. (2002). by hepatitis C virus core protein.
  19. (2008). Cancer-related inflammation.
  20. (2006). Cellular inhibitors of long interspersed element 1 and Alu retrotransposition.
  21. (1995). Chronic hepatitis in patients with active hepatitis B virus and hepatitis C virus combined infections: a histological study.
  22. (2004). Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo.
  23. (2003). Constitutive expression of AID leads to tumorigenesis.
  24. (2004). Cytidine deamination of retroviral DNA by diverse APOBEC proteins.
  25. (2009). Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets.
  26. (2000). Effect of hepatitis B virus mutants on efficacy of vaccination.
  27. (2009). Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection.
  28. (2010). Enhanced expression of lymphomagenesis-related genes in peripheral blood B cells of chronic hepatitis C patients. Clin Immunol;in press.
  29. (2008). Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions.
  30. (2007). Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappaB signaling.
  31. (2005). Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases.
  32. (2005). Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors.
  33. (2000). Frequent integration of precore/core mutants of hepatitis B virus in human hepatocellular carcinoma tissues.
  34. (2010). G to A hypermutation of TT virus.
  35. (2009). G-to-A hypermutation in hepatitis B virus (HBV) and clinical course of patients with chronic HBV infection.
  36. (2009). Genetic editing of HBV DNA by monodomain human APOBEC3 cytidine deaminases and the recombinant nature of APOBEC3G. PLoS
  37. (2004). Global effect of PEG-IFN-alpha and ribavirin on gene expression in PBMC in vitro.
  38. (2007). Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium.
  39. (2007). Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C.
  40. (2008). Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein.
  41. (2004). Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes.
  42. (2001). Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells.
  43. (2006). Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity.
  44. (2009). Inflammation and cancer: how friendly is the relationship for cancer patients?
  45. (2004). Inhibition of Hepatitis B Virus Replication by APOBEC3G. Science 303: 1829.
  46. (2006). Interferoninducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication.
  47. (2005). Liver histology in patients with HBsAg negative anti-HBc and anti-HCV positive chronic hepatitis.
  48. (1994). Loss of conserved cysteine residues in the attachment (G) glycoprotein of two human respiratory syncytial virus escape mutants that contain multiple A–G substitutions (hypermutations).
  49. (2006). Lymphoid neogenesis in chronic inflammatory diseases.
  50. (2009). Murine APOBEC1 is a powerful mutator of retroviral and cellular RNA in vitro and in vivo.
  51. (2004). Mutation of the ‘‘a’’ determinant of HBsAg with discordant HBsAg diagnostic kits.
  52. (2008). Organspecific profiles of genetic changes in cancers caused by activation-induced cytidine deaminase expression.
  53. (2006). Point mutations upstream of hepatitis B virus core gene affect DNA replication at the step of core protein expression.
  54. (2007). Population stratification of a common APOBEC gene deletion polymorphism.
  55. (2003). Processive AIDcatalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation.
  56. (2008). Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.
  57. (2005). Recovery of APOBEC3-edited human immunodeficiency virus GRA hypermutants by differential DNA denaturation PCR.
  58. (2006). Recruitment and activation of naive T cells in the islets by lymphotoxin beta receptor-dependent tertiary lymphoid structure.
  59. (2002). Replicating hepatitis delta virus RNA is edited in the nucleus by the small form of ADAR1.
  60. (2006). Restriction of foamy viruses by APOBEC cytidine deaminases.
  61. (2004). Retroviral restriction by APOBEC proteins.
  62. (1996). RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase.
  63. (2004). Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity.
  64. (2003). Speciesspecific exclusion of APOBEC3G from HIV-1 virions by Vif.
  65. (1999). Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells.
  66. (1993). Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells.
  67. (2003). The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.
  68. (2007). The interferon-induced expression of APOBEC3G in human blood-brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system.
  69. (2003). The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.
  70. (2001). Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen.
  71. (1990). Vaccine-induced escape mutant of hepatitis B virus.